Praliciguat

Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease

Journal of Pharmacology and Experimental Therapeutics (2018)

Jenny V. Tobin, Daniel P. Zimmer, Courtney Shea, Peter Germano, Sylvie G. Bernier, Guang Liu, Kim Long, Joy Miyashiro, Sheila Ranganath, Sarah Jacobson, Kim Tang, G-Yoon Jamie Im, James Sheppeck, Joel D. Moore, Kristine Sykes, James Wakefield, Renee Sarno, Ali R. Banijamali, Albert T. Profy, G. Todd Milne, Mark G. Currie and Jaime L. Masferrer

This article provides an overview of the preclinical profile of praliciguat, known as IW-1973 at the time of publication.

Praliciguat treatment induced a marked and sustained decrease in mean arterial pressure in a rat model of hypertension

Mean arterial pressure in Dahl salt-sensitive rats fed either a normal diet or a high-salt diet. Rats fed a high-salt diet were either untreated or treated with praliciguat (1, 3, and 10 mg/kg in chow), or losartan (30 mg/kg, in drinking water). Data are shown as mean+SEM (mmHg); n=8 per group. Tobin et al. J Pharmacol Exp Ther 2018;365:664-675. Copyright © 2018 The Author(s).

Return to Archive
Top